ABSTRACT
INTRODUCTION
The retinal changes in diabetic retinopathy are a consequence of a damage in retinal microvasculature. The retinal cells involved in diabetic retinopathy are endothelial cells and neuronal cells. Studies around these days showed that significant neuronal damage is an earlier event that vascular damage. 3 Diabetes can caused neural apoptosis by several mechanisms, include: ischemia, oxidative stress, glutamate excitotoxity, neuroinflamation, and increased activity of aldose reducatse. 4 Ganglion cells, in the inner layer of the retina, are the most involved cells in the pathological process in diabetes. 5 Citidine diphosphocoline (CDP-choline or citicoline) CDP-choline is an essential intermediate in the synthesis of structural phospholipids of cell membranes, phosphatidylcholine. 6 After neural death process, exogen citicoline will participate in the phospholipid synthesis at the neuronal membrane cells. Several studies also reported that citicoline also have neuroprotective effect in retinal ganglion cells and promotes nerve regeneration in vitro.
Electroretinography examination is an electric functional examination that aims to evaluate the retina function. Pattern electroretinography (PERG) is a retinal biopotential evoked by a patterned checkerboard stimulus. There are two components in PERG, which are P50 and N95 amplitudes. PERG can provide information about the macular and retinal ganglion cell function. 8 These retinal ganglion cells are influenced by oral citicoline. The management of diabetic retinopathy in the early phase is limited by risk factors controlled, such as hiperglycemia, hypertension, and dyslipidemia. While in diabetes mellitus, the ischemia caused by the gyperglicemia activates a number of proinflammatory pathways, and cause a long-lasting persistent effect even after the blood glucose is normal (hyperglicemic memory).
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Thus, the aim of this study is to evaluate the effect of oral citicoline on electroretinography in patients with NPDR.
METHODS
This study was a prospective, double blind, randomized clinical trial study, and held in Vitreoretina and Neuroophthalmology division KiranaCipto Mangkunkusumo hospital from March to July 2016. Ethical approval and informed consent were obtained.
The inclusion criteria was patients in moderate / severe NPDR which has not been treated by PRP, aged 20-65 years old, and HBA1c < 8%. Patients will be excluded if the bestcorrected visual acuity < 20/50, significant media opacity (moderate -severe), macular / optic nerve disease other than diabetic retinopathy, and previous antioxidant / neuroprotective treatment within 2 weeks. Patient with worsen progressitivity of the disease who needs the PRP treatment, having a protocol violation, or loss to follow up will be dropped out from this study.
Consecutive sampling was done and subjects were randomized (block randomization) into 2 groups: placebo and citicoline. Only one eye which met the criteria included in the study. Subject who met inclusion and exclusion criteria underwent BCA examination using EDTRS chart, funduscopy with 78D lens, fundus photograph, and ERG examination (PERG and full-field ERG). All electrophysiological examinations were performed using an ISCEV standard. The subjects under examination were seated in an acoustically isolated semi-dark room in front of a display surrounded by a uniform field (120 · 120 degree) of luminance (5 cd/m2).
The visual stimuli were checkerboard patterns (contrast was 93 %, mean luminance 100 cd/m2) generated on a television monitor and reversed in contrast at the rate of 4 reversals per second. The electrode used was DTL-plus. The pharmacologic treatment was given for 4 weeks in a daily intraoral dose of 1000 mg citicoline or placebo.
The primary outcome in this study was P50 amplitude and N95 amplitude, with BCVA as a secondary outcome. Evaluation was done in 4 weeks post intervention. The side effect of the drugs was also recorded, Statistical analysis was performed using SPSS 21.0. The numeric data is analyzed with t test or Mann-Whitney test. Paired t-test was used to compare mean amplitude P50 and N95 amplitude within group.
RESULT
There were 38 eyes included in the beginning of the study. 4 subjects were dropped out because of 2 subjects had gastrointestinal discomfort and 2 subjects were loss to follow up. Thirty-four eyes were analyzed, with 18 eyes in citicoline group and 16 eyes in placebo groups. Table 1 shows the baseline characteristic of patients in the study include: age, gender, HbA1c, duration of DM, dyslipidemia, hypertension, and degree of retinopathy with or without macular edema. Baseline characteristics of the subjects in both groups were similar (p > 0.05). Table 2 shows the baseline data before the intervention in two groups; include P50 amplitude, N95 amplitude, and BCVA. The statistical analysis from the two groups were p > 0.05, which can be concluded that all data from both groups were similar.
The P50 and N95 amplitude was assessed at day-0 (baseline) and 4 weeks post intervention. Clinically, the result in citicoline groups showed improvement in all variables. Median P50 amplitude before treatment, 3.1 µV, increased to 3.8 µV (p = 0.89), median N95 amplitude increased from 4.85 µV to 5.7 µV (p = 0.04), and median BCVA LogMar improved from 0.13 LogMar to 0.10 LogMar (p = 0.02). In placebo group, only P50 amplitude improved from 3.5 µV to 4.5 µV (p = 0.10). Figure 1 and 2 show the comparison in P50 and N95 amplitude post intervention between two groups. Table 3 exhibited a comparison in delta examination after the intervention in both groups. Delta examination results were obtained from the amplitude difference between the pre and post intervention. Delta N95 amplitude was higher in citcioline group (p = 0.35) while the delta P50 amplitude was higher in the placebo group (p = 0.45). Total subjects in this study were 38 subjects. There were four-drop outs. After the randomization table was openned, we found that these subjects were from placebo groups. 
DISCUSSION
Variables included in the baseline characteristics were gender, age, HbaA1c, duration of DM, hypertension, dyslipidemia, and degree of retinopathy. The proportion of the gender in this study is almost equal between the female and male, with percentages of 56% female and 44% male. Similar data was reported by Yau et al 10 , that the prevalence of diabetic retinopathy in women (52%) and men (48%) are the same. The mean age of the subjects in this study was 56.24 ± 1.25 years old. This characteristics was similar to epidemiological studies conducted in 22.896 subjects of American, Australian, European, and Asian, with mean age of 58.1 years old.
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This study included only subjects with HbA1c levels < 8%. David MD, et al 11 reported that the risk of progression in diabetic retinopathy is associated with HbA1c levels in one's blood. Study from Raman 12 also reported that the levels of HbA1c > 8% was significantly associated with the incidence of sight-threatening diabetic retinopathy (severe NPDR, proliferative diabetic retinopathy and clinically significant macular edema). Diabetic retinopathy is a multifactorial microvascular complications associated with hyperglycemia, hypertension, and high lipid levels in the blood. The proportion of subjects with hypertension in this study was 26.5%. Wisconsin study also reported that the prevalence of hypertension in type 1 diabetes was 17.3% and 25.9% after 10 years of diabetes. 13 Chew et al 14 in the Early Treatment Diabetic Retinopathy Study (EDTRS) reported patients with elevated levels of total cholesterols and high LDL may exacerbate the occurance of retinopathy and the formation of hard exudates.
One of the purposes of this study was to evaluate the results of the examination before and after the intervention within group. P50 amplitude was clinically improved in both groups before and after treatment, but these values were not statistically significant (p> 0.05). P50 amplitude was increased higher in the placebo group. The P50 component is more specific to be an indicator of macular function.
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Improvement in the P50 amplitude could be caused by improvement of subject's risk factors, such as hypertension and dylipidemia that lead to reduction in hard exudates and intraretinal hemorrhages in the macula. All subjects in this study were consulted to the internist at the first visit. Idiculla et al 16 reported that serum lipids has a significant connection with the formation of hard exudates, clinically significant macular edema (CSME), and loss of visual acuity in type 2 diabetes. Study by Rusenberg 17 reported that diabetes could cause swelling and beading on the dendrites and axons of retinal ganglion cells. N95 in PERG is a component that reflects the retinal ganglion cell layer. Several studies reported that N95 amplitude is directly related to the volume of retinal ganglion cells. Exogenous citicoline can increase the formation of phosphatidylcholine (ptdCho) and phospholipids, stabilizes the intracellular conditions of neuronal cells, decrease the activity of phospholipase A2 enzyme (PLA2), and antipoptosis in mitochondria pathway. [18] [19] [20] [21] [22] [23] Figure 2 shows that pre-and postintervention N95 amplitude only inrease in citicoline group. There was an increase in the median of N95 amplitude before treatment, 4.85 µV, to 5.7 µV after treatment, which statistically significant (p=0.04) in citicoline group. Previous study regarding the used of citicoline in glaucoma and NAION also reported similar ideas. Parisi 24 reported that the administration of intramuscular citicoline in 1000 mg/day for 60 days in patients with glaucoma might improve the visual function as suggested by the increase in P50-N95 amplitude and N75-P100 VEP. Parisi 25 also had research on citicoline administration in patients with NAION. In his research, citicoline given in 1600 mg/diem for 60 day P = 0.04 P = 0.68 P = 0.89
improved the PERG and VEP in patients. The secondary outcome of this research is BCVA variable. The BCVA improved by 0.03 LogMar in citicoline group, with p value of 0.02. This finding is consistent with previous study that also reported that citicoline can improve visual acuity. Citicoline is a neuroprotective agent, which plays an important role in the synthesis of phospholipid in cell membrane. Additional functions of phospholipid in neuronal membrane is to impulse conduction of nerve cells and neurotransmitter. 6 Another objective of this study was to look at the differences in test results pre-and post-intervention in both groups (intergroup). Table 3 shows that the N95 amplitude in citicoline group had better improvement that the placebo group, but unfortunately from the statistically analysis, the p value was > 0.05. This value could be explained by several reasons, such as: distribution value was abnormal in both groups, which made the standard deviation was quite large. Standard deviation entered in the calculation of the sample in this study was 0.7 µV, while the standard deviation obtained from the results is 1.9 µV. Wide variation in this study is probably because of differences in visual acuity. severity of retinopathy, and large variations in duration of DM.
Total subject in this research is 38. Only 2 subjects had gastroinstetinal complaint after the intervention. These two subjects were from placebo group. There was zero person from the citicoline group. This result is similar to other studies that reported citicoline are safe and the side effects that are attributable to this drug are rare. The side effect consist mainly of headache and gastrointestinal discomfort (5.01%).
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CONCLUSION
Daily dose 1000 mg of citicoline given in 4 weeks may induce a significant improvement in mean N95 amplitude before and after the treatment. In placebo group, there was a positive trend in P50 amplitude while in citicoline group showed positive trend in N95 amplitude, but these values were not statistically significant.
